{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology', 'Phase II liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria', 'ALT-absolute', 'ALT 5xULN', 'ALT Increase', 'ALT: 3xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)', 'INR\u00b2', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT: 3xULN and cannot be monitored weekly for 4 weeks', 'Monitor', 'Symptomatic\u00b3', 'ALT 3xULN associated with symptoms (new or worsening) believed', 'to be related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Obtain INR and recheck with each', 'liver chemistry assessment until the', 'Complete the liver event CRF and complete', 'transaminases values show', 'an SAE data collection tool if the event also', 'downward trend', 'meets the criteria for an SAE\u00b2', 'Obtain blood sample for', 'Perform liver chemistry event follow up', 'pharmacokinetic (PK) analysis, up', 'assessments', 'to 72 h after last dose5', 'Monitor the participant until liver', 'chemistries resolve, stabilize, or return to', 'Serum creatine phosphokinase', 'within baseline (see MONITORING', '(CPK) and lactate dehydrogenase', '(LDH).', 'below)', 'Fractionate bilirubin, if total', 'Do not restart/rechallenge participant', 'bilirubin 2xULN', 'with study treatment unless allowed per', 'protocol and GSK Medical Governance', 'Obtain complete blood count with', 'approval is granted (see below)', 'differential to assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or', 'protocol or not granted, permanently', 'worsening of clinical symptoms of', '76']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'discontinue study treatment and continue', 'liver injury, or hypersensitivity, on', 'participant in the study for any protocol', 'the AE report form', 'specified follow up assessments', 'Record use of concomitant', 'medications on the concomitant', 'MONITORING:', 'medications report form including', 'acetaminophen, herbal remedies,', 'For bilirubin or INR criteria:', 'other over the counter medications.', 'Repeat liver chemistries (include ALT,', 'Record alcohol use on the liver', 'AST, alkaline phosphatase, bilirubin) and', 'event alcohol intake case report', 'perform liver event follow up assessments', 'form (CRF) page', 'within 24 hrs', 'Monitor participants twice weekly until', 'liver chemistries resolve, stabilize or return', 'to within baseline', 'For bilirubin or INR criteria:', 'A specialist or hepatology consultation is', 'Anti-nuclear antibody, anti-smooth', 'recommended', 'muscle antibody, Type 1 anti-liver', 'kidney microsomal antibodies, and', 'For All other criteria:', 'quantitative total immunoglobulin', 'Repeat liver chemistries (include ALT,', 'G (IgG) or gamma globulins.', 'AST, alkaline phosphatase, bilirubin) and', 'Serum acetaminophen adduct high', 'perform liver event follow up assessments', 'performance liquid chromatography', 'within 24-72 hrs', '(HPLC) assay (quantifies potential', 'Monitor participants weekly until liver', 'acetaminophen contribution to liver', 'chemistries resolve, stabilize or return to', 'injury in participants with definite', 'within baseline', 'or likely acetaminophen use in the', 'preceding week [James, 2009].', 'Liver imaging (ultrasound,', 'magnetic resonance, or', 'computerised tomography) and /or', 'liver biopsy to evaluate liver', 'disease complete Liver Imaging', 'and/or Liver Biopsy CRF pages.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 2xULN..', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM);', 'Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable,', 'obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody', '77']\n\n###\n\n", "completion": "END"}